JP2018512151A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512151A5 JP2018512151A5 JP2017553119A JP2017553119A JP2018512151A5 JP 2018512151 A5 JP2018512151 A5 JP 2018512151A5 JP 2017553119 A JP2017553119 A JP 2017553119A JP 2017553119 A JP2017553119 A JP 2017553119A JP 2018512151 A5 JP2018512151 A5 JP 2018512151A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- mutein
- human
- cells
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091006020 Fc-tagged proteins Proteins 0.000 claims 21
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 102000039446 nucleic acids Human genes 0.000 claims 11
- 108020004707 nucleic acids Proteins 0.000 claims 11
- 150000007523 nucleic acids Chemical class 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 10
- 108010002350 Interleukin-2 Proteins 0.000 claims 9
- 102000000588 Interleukin-2 Human genes 0.000 claims 9
- 238000006467 substitution reaction Methods 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 210000003289 regulatory T cell Anatomy 0.000 claims 6
- 230000035772 mutation Effects 0.000 claims 5
- 102200105319 rs397514675 Human genes 0.000 claims 5
- 230000037430 deletion Effects 0.000 claims 4
- 238000012217 deletion Methods 0.000 claims 4
- 102220595293 Minor histocompatibility protein HB-1_H16Y_mutation Human genes 0.000 claims 3
- 102220546830 Nuclear pore complex protein Nup85_L19A_mutation Human genes 0.000 claims 3
- 102220472091 Protein ENL_D20T_mutation Human genes 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 102220110995 rs115116507 Human genes 0.000 claims 3
- 102220579314 ARF GTPase-activating protein GIT1_L12S_mutation Human genes 0.000 claims 2
- 206010000234 Abortion spontaneous Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000012657 Atopic disease Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000009137 Behcet syndrome Diseases 0.000 claims 2
- 102220638990 Beta-enolase_H16A_mutation Human genes 0.000 claims 2
- 102220638992 Beta-enolase_H16D_mutation Human genes 0.000 claims 2
- 102220638984 Beta-enolase_H16K_mutation Human genes 0.000 claims 2
- 102220638986 Beta-enolase_H16S_mutation Human genes 0.000 claims 2
- 208000005176 Hepatitis C Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- 102220546836 Nuclear pore complex protein Nup85_L19D_mutation Human genes 0.000 claims 2
- 102220550572 Proteasome maturation protein_L19E_mutation Human genes 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 238000007792 addition Methods 0.000 claims 2
- 208000004631 alopecia areata Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 208000024711 extrinsic asthma Diseases 0.000 claims 2
- 230000013595 glycosylation Effects 0.000 claims 2
- 238000006206 glycosylation reaction Methods 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 210000005259 peripheral blood Anatomy 0.000 claims 2
- 239000011886 peripheral blood Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 102200000390 rs121917859 Human genes 0.000 claims 2
- 102200066678 rs1554618767 Human genes 0.000 claims 2
- 102220112880 rs370986101 Human genes 0.000 claims 2
- 102220013748 rs397516745 Human genes 0.000 claims 2
- 102220120718 rs886042647 Human genes 0.000 claims 2
- 208000000995 spontaneous abortion Diseases 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 102220626060 HMG box transcription factor BBX_D84A_mutation Human genes 0.000 claims 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 1
- 102220479935 Leucine-rich repeat-containing protein 26_R81A_mutation Human genes 0.000 claims 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 1
- 102220595270 Minor histocompatibility protein HB-1_H16R_mutation Human genes 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 claims 1
- 102000008300 Mutant Proteins Human genes 0.000 claims 1
- 108010021466 Mutant Proteins Proteins 0.000 claims 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 1
- 102220640550 Putative oxidoreductase GLYR1_L19S_mutation Human genes 0.000 claims 1
- 102220351326 c.35T>A Human genes 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 102000055277 human IL2 Human genes 0.000 claims 1
- 238000011577 humanized mouse model Methods 0.000 claims 1
- 238000000099 in vitro assay Methods 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 102200068760 rs1805006 Human genes 0.000 claims 1
- 102200139516 rs35960830 Human genes 0.000 claims 1
- 102220105333 rs730882078 Human genes 0.000 claims 1
- 102220217104 rs779385322 Human genes 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021096449A JP2021153593A (ja) | 2016-05-04 | 2021-06-09 | 制御性ｔ細胞の増殖のためのインターロイキン−２変異タンパク質 |
| JP2023106755A JP7649349B2 (ja) | 2016-05-04 | 2023-06-29 | 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2016/030843 WO2016164937A2 (en) | 2015-04-10 | 2016-05-04 | Interleukin-2 muteins for the expansion of t-regulatory cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021096449A Division JP2021153593A (ja) | 2016-05-04 | 2021-06-09 | 制御性ｔ細胞の増殖のためのインターロイキン−２変異タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018512151A JP2018512151A (ja) | 2018-05-17 |
| JP2018512151A5 true JP2018512151A5 (enExample) | 2019-06-06 |
| JP7422480B2 JP7422480B2 (ja) | 2024-01-26 |
Family
ID=61598336
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017553119A Active JP7422480B2 (ja) | 2016-05-04 | 2016-05-04 | 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質 |
| JP2021096449A Pending JP2021153593A (ja) | 2016-05-04 | 2021-06-09 | 制御性ｔ細胞の増殖のためのインターロイキン−２変異タンパク質 |
| JP2023106755A Active JP7649349B2 (ja) | 2016-05-04 | 2023-06-29 | 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021096449A Pending JP2021153593A (ja) | 2016-05-04 | 2021-06-09 | 制御性ｔ細胞の増殖のためのインターロイキン−２変異タンパク質 |
| JP2023106755A Active JP7649349B2 (ja) | 2016-05-04 | 2023-06-29 | 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質 |
Country Status (5)
| Country | Link |
|---|---|
| EP (2) | EP3280725B1 (enExample) |
| JP (3) | JP7422480B2 (enExample) |
| KR (3) | KR20240115933A (enExample) |
| CN (2) | CN115073581A (enExample) |
| NZ (1) | NZ775714A (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL321812A (en) | 2017-08-03 | 2025-08-01 | Synthorx Inc | Cytokine complexes for the treatment of autoimmune diseases |
| AU2019288496B2 (en) * | 2018-06-22 | 2024-11-21 | Cugene Inc. | Interleukin-2 variants and methods of uses thereof |
| HUE062719T2 (hu) * | 2018-06-29 | 2023-11-28 | Akston Biosciences Corp | Ultra-hosszú hatású inzulin-FC fúziós fehérjék és az alkalmazási eljárások |
| TW202031284A (zh) | 2018-11-08 | 2020-09-01 | 美商新索思股份有限公司 | 介白素10結合物及其用途 |
| CN113924311A (zh) * | 2019-01-07 | 2022-01-11 | 印希比股份有限公司 | 包含修饰的il-2多肽的多肽及其用途 |
| MA54952A (fr) | 2019-02-06 | 2022-05-11 | Synthorx Inc | Conjugués d'il-2 et méthodes d'utilisation de ceux-ci |
| PH12022550165A1 (en) * | 2019-07-26 | 2023-05-08 | Visterra Inc | Interleukin-2 agents and uses thereof |
| CN114555634B (zh) * | 2019-08-13 | 2025-01-10 | 美国安进公司 | 用于扩增调节性t细胞的白介素-2突变蛋白 |
| AU2020329933A1 (en) * | 2019-08-15 | 2022-03-24 | Cytimm Therapeutics, Inc. | Modified interleukin 2 (IL-2) polypeptides, conjugates and uses thereof |
| CA3148135A1 (en) | 2019-08-23 | 2021-03-04 | Carolina E. CAFFARO | Il-15 conjugates and uses thereof |
| CN110642934B (zh) * | 2019-09-10 | 2022-08-23 | 中国医学科学院北京协和医院 | 靶向调节t细胞的长效白介素-2及其在治疗自身免疫病中的应用 |
| WO2021050554A1 (en) | 2019-09-10 | 2021-03-18 | Synthorx, Inc. | Il-2 conjugates and methods of use to treat autoimmune diseases |
| PE20221506A1 (es) * | 2019-12-17 | 2022-10-04 | Amgen Inc | Agonista doble de interleucina-2/receptor de tnf para uso en terapia |
| KR20220140514A (ko) | 2020-01-10 | 2022-10-18 | 브라이트 피크 테라퓨틱스 아게 | 변형된 il-2 폴리펩타이드 및 그의 용도 |
| EP4108683A4 (en) * | 2020-02-21 | 2024-04-03 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | ANTI-IL-2 ANTIBODIES, ANTIGEN-BINDING FRAGMENT THEREOF AND MEDICAL USE THEREOF |
| AR121713A1 (es) * | 2020-03-31 | 2022-06-29 | Hanmi Pharm Ind Co Ltd | Nuevos análogos de il-2 inmunoestimulantes |
| EP4175979A2 (en) * | 2020-07-02 | 2023-05-10 | Inhibrx, Inc. | Polypeptides comprising modified il-2 polypeptides and uses thereof |
| KR20230060514A (ko) * | 2020-09-01 | 2023-05-04 | 다케다 야쿠힌 고교 가부시키가이샤 | 인터루킨-2 뮤테인 및 이의 용도 |
| CN116323653A (zh) * | 2020-09-04 | 2023-06-23 | 山东先声生物制药有限公司 | Il-2突变体及其应用 |
| CA3203977A1 (en) * | 2020-12-04 | 2022-06-09 | Visterra, Inc. | Methods of using interleukin-2 agents |
| IL304365B2 (en) * | 2021-03-31 | 2025-04-01 | Hanmi Pharmaceutical Co Ltd | A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof |
| WO2022221746A1 (en) * | 2021-04-16 | 2022-10-20 | Orionis Biosciences, Inc. | Il-2 based constructs |
| JP2024536840A (ja) * | 2021-09-26 | 2024-10-08 | ウーシー バイオロジクス アイルランド リミテッド | Ｉｌ－２バリアント及びその融合タンパク質 |
| TW202333772A (zh) | 2021-12-01 | 2023-09-01 | 美商威特拉公司 | 使用介白素-2藥劑之方法 |
| CA3245295A1 (en) * | 2022-03-03 | 2025-06-13 | Hainan Simcere Pharmaceutical Co., Ltd. | Pharmaceutical Composition of Il2 Antibody-Mutant FC Block Fusion Protein and its Use |
| CN117003851A (zh) * | 2022-04-27 | 2023-11-07 | 康源博创生物科技(北京)有限公司 | 一种白细胞介素-2突变蛋白 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
| CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
| US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
| CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
| US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
| US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
| WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| WO1991018982A1 (en) | 1990-06-05 | 1991-12-12 | Immunex Corporation | Type ii interleukin-1 receptors |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US6239328B1 (en) | 1992-10-05 | 2001-05-29 | North Carolina State University | Method for reducing expression variability of transgenes in plant cells |
| US6037525A (en) | 1996-08-01 | 2000-03-14 | North Carolina State University | Method for reducing expression variability of transgenes in plant cells |
| US6245974B1 (en) | 1997-08-06 | 2001-06-12 | North Carolina State University | Matrix attachment regions |
| DZ2788A1 (fr) * | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| US6177612B1 (en) | 1998-07-31 | 2001-01-23 | Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture And Agri-Food Canada | Matrix attachment regions |
| AU762382B2 (en) | 1998-09-29 | 2003-06-26 | Pioneer Hi-Bred International, Inc. | MAR/SAR elements flanking RSYN7-driven construct |
| KR100408844B1 (ko) | 2000-07-29 | 2003-12-06 | 한국산업기술평가원 | 동물세포 발현벡터 |
| US7259010B2 (en) | 2000-12-15 | 2007-08-21 | Pangen Biotech Inc. | Expression vector for animal cell containing nuclear matrix attachment region of interferon beta |
| DK1395669T3 (da) | 2001-01-26 | 2009-11-16 | Selexis Sa | Matriks bindingsregioner og fremgangsmåder til anvendelse af disse |
| EP1454138B1 (en) * | 2001-12-04 | 2012-01-18 | Merck Patent GmbH | Immunocytokines with modulated selectivity |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| EP1694850B1 (en) | 2003-11-12 | 2011-06-29 | Schering Corporation | Plasmid system for multigene expression |
| KR20070003934A (ko) * | 2004-03-05 | 2007-01-05 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템 |
| US20060069515A1 (en) * | 2004-09-30 | 2006-03-30 | International Business Machines Corporation | Method and system for protein folding trajectory analysis using patterned clusters |
| JP2008543839A (ja) | 2005-06-14 | 2008-12-04 | アムジェン インコーポレーテッド | 自己緩衝タンパク質製剤 |
| US7695963B2 (en) | 2007-09-24 | 2010-04-13 | Cythera, Inc. | Methods for increasing definitive endoderm production |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| DE102008023820A1 (de) * | 2008-05-08 | 2009-11-12 | Aicuris Gmbh & Co. Kg | Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen |
| WO2010085495A1 (en) * | 2009-01-21 | 2010-07-29 | Amgen Inc. | Compositions and methods of treating inflammatory and autoimmune diseases |
| EP2504360B1 (en) | 2009-11-23 | 2018-08-15 | Amgen Inc. | Monomeric antibody fc |
| US9580486B2 (en) * | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
| EP2968450A4 (en) * | 2013-03-15 | 2016-10-26 | Angelica Therapeutics Inc | MODIFIED TOXINS |
| US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
| KR102493543B1 (ko) * | 2014-07-21 | 2023-01-30 | 데리니아, 인크. | 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자 |
| JP6640834B2 (ja) * | 2014-08-11 | 2020-02-05 | デリニア， インコーポレイテッド | 自己免疫疾患の処置のために調節性ｔ細胞を選択的に活性化させる改変ｉｌ−２変異体 |
-
2016
- 2016-05-04 KR KR1020247024111A patent/KR20240115933A/ko not_active Ceased
- 2016-05-04 EP EP16726999.2A patent/EP3280725B1/en active Active
- 2016-05-04 JP JP2017553119A patent/JP7422480B2/ja active Active
- 2016-05-04 CN CN202210486963.1A patent/CN115073581A/zh active Pending
- 2016-05-04 CN CN201680033372.1A patent/CN109071623B/zh active Active
- 2016-05-04 NZ NZ775714A patent/NZ775714A/en unknown
- 2016-05-04 KR KR1020257029040A patent/KR20250133490A/ko active Pending
- 2016-05-04 KR KR1020177032587A patent/KR102687530B1/ko active Active
- 2016-05-04 EP EP20190744.1A patent/EP3808764A1/en active Pending
-
2021
- 2021-06-09 JP JP2021096449A patent/JP2021153593A/ja active Pending
-
2023
- 2023-06-29 JP JP2023106755A patent/JP7649349B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023134534A5 (enExample) | ||
| Hernandez et al. | Engineering IL-2 for immunotherapy of autoimmunity and cancer | |
| Ferreira et al. | Next-generation regulatory T cell therapy | |
| EP3551653B1 (en) | T cell receptors with improved pairing | |
| Huang et al. | Airway inflammation and IgE production induced by dust mite allergen-specific memory/effector Th2 cell line can be effectively attenuated by IL-35 | |
| Elinav et al. | Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor | |
| JPH07508179A (ja) | ヒトインターロイキン−１３ | |
| JP2025106233A5 (enExample) | ||
| AU2005291039A1 (en) | T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents | |
| KR20160010466A (ko) | Ｉｃｏｓｌ에 대한 치료학적 표적 특이적 ｖｎａｒ 도메인의 단리 | |
| JP2016518823A5 (enExample) | ||
| CN114901678A (zh) | 肽-mhc ii蛋白构建体及其用途 | |
| Hasan et al. | Defining a T-cell epitope within HSP 65 in recurrent aphthous stomatitis | |
| Karlen et al. | Biological and molecular characteristics of interleukin-5 and its receptor | |
| Guo et al. | Protection against Th17 cells differentiation by an interleukin-23 receptor cytokine-binding homology region | |
| CN107207622B (zh) | Hla-b27同二聚体用于癌症治疗的用途 | |
| CN114901684B (zh) | 粒细胞集落刺激因子受体(g-csfr)的经修饰胞外结构域和结合其的细胞因子 | |
| CN108640991B (zh) | 抗人白介素17a单克隆抗体及其应用 | |
| EP4326402A2 (en) | Antigen presenting polypeptide complexes bearing tgf-beta and methods of use thereof | |
| JP2008500812A (ja) | 免疫抑制サイトカイン | |
| Ishizaka | Regulation of the IgE antibody response | |
| JP2023536100A (ja) | 代替の翻訳開始および翻訳停止に由来する多機能免疫グロブリンフォールドポリペプチド | |
| Shin et al. | Cloning, expression and bioassay of canine CTLA4Ig | |
| JP7518915B2 (ja) | Ｃｄ３融合タンパク質およびその使用 | |
| WO2021160124A1 (zh) | 嵌合抗原受体的优化 |